IFN-γ drives long-term bone marrow niche dysfunction following chemotherapy Free

Since their introduction in the 1960s, chemotherapy agents have remained a cornerstone of treatment for hematopoietic malignancies. However, their non-specific cytotoxic effects extend beyond malignant cells, inflicting collateral damage on healthy tissues. Hematopoiesis is supported by the bone marrow (BM) microenvironment, where mesenchymal stromal cells (MSCs) and vascular endothelial cells (ECs) provide critical factors for hematopoietic stem cell (HSC) quiescence, self-renewal, and differentiation. Clinical observations indicate that leukemia patients exposed to high-dose chemotherapy retain a diminished hematopoietic progenitor pool years after transplantation, despite normalized peripheral blood counts, suggesting long-term impairment of the BM niche. Yet, the cellular and molecular mechanisms underlying this persistent dysfunction remain poorly understood.

Here, we demonstrate that doxorubicin (DOX), a widely used anthracycline in treatment of leukemia, lymphoma and breast cancer, induces long-term remodeling of the BM niche. Mice administrated serial DOX treatment exhibited acute lymphopenia and expansion of hematopoietic progenitors. While mature hematopoietic populations were fully restored to baseline by 8 weeks (w), we observed a persistent increase in phenotypic HSCs, suggesting a sustained loss of HSC quiescence. Next, to specifically examine the impact of DOX on the hematopoietic supportive capacity of the BM niche, we transplanted HSCs into DOX or control-treated recipients. Sixteen weeks post-transplant, we observed diminished donor HSC pool in DOX-treated hosts, indicating impaired HSC maintenance by the BM niche.

Single cell transcriptomics and functional assays revealed that DOX disrupts both stromal and vascular compartment of the BM niche. MSCs displayed reduced ex vivo colony forming capacity and impaired in vivo differentiation towards osteoblasts and adipocytes, leading to the accumulation of undifferentiated, dysfunctional MSCs 20w post-treatment. Consequently, DOX-treated mice showed pronounced trabecular loss, decreased skeletal mechanical strength and delayed fracture healing-features that align with bone complications observed in leukemia patients. In parallel, DOX led to depletion of arteriolar vessels and pericytes, which are essential for maintaining HSC quiescence and niche integrity. Collectively, these results indicate that DOX induced persistent remodeling of the BM microenvironment extends far beyond the treatment window.

Singel cell transcriptomic analyses revealed sustained activation of inflammatory responses in MSCs and ECs 8w following DOX treatment, promoting investigation into the source of inflammation. Multiplex cytokine assays revealed increased interferon gamma (IFNγ) level in BM supernatant, but not serum, implicating localized inflammation. Flow cytometry analysis showed a significant increase in CD8+ T cell and an expansion of effector memory CD8+ T cells. Moreover, elevated IFNγ production was observed in CD8⁺ T cells from DOX-treated mice upon stimulation, indicating prior activation and increased effector function following DOX exposure. Notably, genetic ablation of IFNγ receptor or IFNγ blockade rescued DOX-induced vascular defects and restored MSC adipogenic differentiation. DOX-mediated bone loss was also partially mitigated in mice lacking IFNγ receptor. These results highlighted IFNγ signaling as a central driver of DOX-mediated niche dysfunction.

Together, our data showed that DOX dismantles the cellular architecture of the HSC-supportive niche, replacing it with a chronically inflamed, structurally disordered environment. This dysfunctional niche compromises HSC maintenance, impairs skeletal integrity, and may underlie persistent hematopoietic deficits in cancer survivors. Targeting inflammatory mediators, such as IFNγ, presents a promising therapeutic strategy to preserve niche function, support tissue regeneration, and improve long-term outcomes following chemotherapy.